Skip to main content
Premium Trial:

Request an Annual Quote

Decode Reports 20-Percent Jump in Q3 Revenue, Narrowed Losses; R&D Spend Surges 70 Percent

NEW YORK, Nov. 8 (GenomeWeb News) - Decode Genetics yesterday reported a 20-percent increase in revenues amid narrowed losses for the third quarter.


Decode's revenues for the third quarter rose to $13.2 million from $11 million in the same period a year ago.


The company said R&D spending in the quarter surged nearly 70 percent to $11 million from $6.5 million for the same quarter last year.


Decode narrowed its net losses this quarter by 8.8 percent to $11.4 million, or $.21 per basic share, from $12.5 million, or $.23 per basic share in the year-ago period.


Qiagen had approximately $171 million in cash and cash investments as of Sept. 30.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.